Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial

BACKGROUND: Modest efficacy was reported for the HIV vaccine tested in the RV144 trial, which comprised a canarypox vector (ALVAC) and envelope (env) glycoprotein (gp120). These vaccine components were adapted to express HIV-1 antigens from strains circulating in South Africa, and the adjuvant was c...

Descripción completa

Detalles Bibliográficos
Autores principales: Bekker, Linda-Gail, Moodie, Zoe, Grunenberg, Nicole, Laher, Fatima, Tomaras, Georgia D, Cohen, Kristen W, Allen, Mary, Malahleha, Mookho, Mngadi, Kathryn, Daniels, Brodie, Innes, Craig, Bentley, Carter, Frahm, Nicole, Morris, Daryl E, Morris, Lynn, Mkhize, Nonhlanhla N, Montefiori, David C, Sarzotti-Kelsoe, Marcella, Grant, Shannon, Yu, Chenchen, Mehra, Vijay L, Pensiero, Michael N, Phogat, Sanjay, DiazGranados, Carlos A, Barnett, Susan W, Kanesa-thasan, Niranjan, Koutsoukos, Marguerite, Michael, Nelson L, Robb, Merlin L, Kublin, James G, Gilbert, Peter B, Corey, Lawrence, Gray, Glenda E, McElrath, M Juliana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier B.V 2018
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6028742/
https://www.ncbi.nlm.nih.gov/pubmed/29898870
http://dx.doi.org/10.1016/S2352-3018(18)30071-7

Ejemplares similares

Ejemplares similares